Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum to develop chemo-enhancing agents
Under the terms of the agreement, privately-held Chicago Labs will receive an upfront fee of $100,000, and is eligible to receive payments upon achievement of certain development, regulatory
Under the terms of the agreement, privately-held Chicago Labs will receive an upfront fee of $100,000, and is eligible to receive payments upon achievement of certain development, regulatory
The novel pyrimidine compounds have been shown to control the progress of cells through the cancer cell cycle. One group of the compounds works by inhibiting Cyclin Dependent
If, as expected, the European Commission accepts the recommendation of its Committee for Medicinal Products for Human Use (CHMP), it would be the second major approval of duloxetine
Data from all patients in the study showed a median response duration of more than 45 weeks. Furthermore, analysis of the time to response showed that 85% of
Following this Medicines and Healthcare products Regulatory Agency (MHRA) approval, the trial will now enroll approximately 30 evaluable patients at the Royal Marsden and St James’s Hospitals in
The Committee for Medicinal Products for Human Use (CHMP) concluded that the available data show an increased risk of cardiovascular adverse events for COX-2 inhibitors as a class.
The prostate cancer study is the first trial of Aplidin in solid tumors to be carried out in the US. The objective of the study is to determine
Topigen’s dual-antisense compound, ASM8 targets multiple mediators and has been demonstrated in pre-clinical studies to block two major pathways of the inflammation response, thus shutting down the most
Common chemotherapeutics that Quinamed improves or ‘chemopotentiates’ include cisplatin (Bristol-Myers Squibb’s Platinol), paclitaxel (Bristol-Myers Squibb’s Taxol), vinblastine (Eli Lilly’s Velban) and camptothecin (a trademark of the Research Triangle
According to reports, FDA safety officer David Graham told a conference that Mobic is potentially as dangerous as Vioxx in terms of cardiovascular safety risks. This alleged risk